Important treatment attributes considered by Japanese patients with advanced Parkinson's disease (aPD)

Important treatment attributes considered by Japanese patients with advanced Parkinson's disease (aPD) - Important treatment attributes considered by Japanese patients with advanced Parkinson's disease (aPD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051513

Enrollment

200

Registered

2023-08-01

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosis of Parkinson's Disease (confirmed by a physician) 2) Adults (30 years of age or older) 3) Receiving PD treatment (oral medications and/or applied therapy) in Japan 4) Patients who meet any of the 5-2-1 criteria (defined by physicians) a. Taking oral levodopa five or more times per day b. Off time for more than 2 hours per day c. Troublesome dyskinesia for more than 1 hour per day 5) Able to respond to this survey by themselves (assistance for entering their answers to the web-based questionnaire by their caregivers is allowed) 6) Given consent to the study

Exclusion criteria

Exclusion criteria: 1) Patients with experience in any device-aided therapy (DATs; CSCI, LCIG, or DBS) or FUS 2) Patients with impaired cognitive function (e.g., MMSE under 23, taking medicine for Alzheimer's disease or cognitive impairment (specifically: donepezil HCl, rivastigmine transdermal system, galantamine, galantamine HBr, memantine HCI)), or psychosis (either past history or current) 3) Patients with a diagnosis of atypical or secondary Parkinsonism 4) Patients with visual impairment significant enough that they cannot comply with the study procedures 5) Did not provide consent to participate (and record the interview) 6) Is not willing nor able to comply with procedures required in this protocol 7) Patients who are pregnant 8) Not fluent in Japanese

Design outcomes

Primary

Measure	Time frame
The preference weight and the relative importance (%) of the attributes will be identified by the phase 1 interview conducted in this study in Japanese aPD patients.	—

Secondary

Measure	Time frame
The preference weight and the relative importance (%) of each attribute in each patient subgroup.	—

Countries

Japan

Contacts

Public ContactToshiki Nozaki

AbbVie GK Medical/ Medical Affairs/ Specialty/ Neurology

toshiki.nozaki@abbvie.com080-4127-7549

Outcome results